DV2-HBV-27: Observational Pregnancy Registry

HEPLISAV-B Pregnancy Registry: An Observational Study on the Safety of HEPLISAV-B Exposure in Pregnant Women and Their Offspring

Purpose of the study is to evaluate pregnancy outcomes among women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy

Inclusion Criteria:

• 18 years and older
• HEPLISAV-B exposure within 28 days prior to conception or at any time during pregnancy

Exclusion Criteria:

• Less than 18 years of age
• HEPLISAV-B exposure greater than 28 days prior to conception